Bayern Kapital — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsJeito CapitalBioqube VenturesForbionCanaan PartnersNovartis Venture FundBioGeneration Ventures+2 more
Workerbase offers a connected worker platform for manufacturing that digitizes shopfloor work, delivers guided digital work instructions, orchestrates tasks by worker skill, and connects to factory systems and machines.
Advanced ManufacturingAI & Machine LearningFuture of WorkSaaSMunich, DE
Norman Hartmann(Founding team member)inThorsten Krueger(Founder)in
Co-investorsPoint NineAlmaz CapitalPorsche Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Goodly InnovationsiThera Medical
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.